The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects

Journal of Human Hypertension

Volumn 28, Issue 7, 2014, Pages 432-437

  Ojji, D B ^a,b   Opie, L H ^b   Lecour, S ^b   Lacerda, L ^b   Adeyemi, O M ^a   Sliwa, K ^b  

^a UNIVERSITY OF ABUJA   (Nigeria)

^b Hatter Institute for Cardiovascular Research in Africa   (South Africa)

Author keywords

hypertensive heart failure; ST2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; INTERLEUKIN 1 RECEPTOR; ST2 PROTEIN; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; BLOOD LEVEL; CHEMOLUMINESCENCE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; AGED; BLOOD; COHORT ANALYSIS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; COHORT STUDIES; ECHOCARDIOGRAPHY; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; VENTRICULAR REMODELING;

EID: 84927176302     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.130     Document Type: Article

References (31)

1. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000; 191: 1069-1076.
2. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivary C, Tominaga S, Solomon SD et al. Expression and regulation of ST2, and interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106: 2961-2962.
3. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003; 107: 721-726.
4. Sabatine MS, Morrow DA, Higgins LJ, MacGillivary C, Guo W, Bode C et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008; 117: 1936-1944.
5. Diez J. Serum soluble ST2 as a biochemical marker of acute heart failure: future areas of research. JACC 2008; 52(18): 1466-1467.
6. Rehman S, Mueller T, Januzzi J. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008; 52: 1458-1465.
7. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RRJ, Januzzi JL. Serum levels of the interleukin-1 receptor family member st2, cardiac structure and function, and long-term mortality in patients with acute dyspnoea. Circ Heart Fail 2009; 2: 311-319.
8. US Department of Health and Human Sciences. The seventh report of the joint national committee on prevention, evaluation and treatment of high blood pressure. NIH Publication 2004; 04: 5230.
9. Ojji D, Stewart S, Ajayi S, Mamven M, Sliwa K. A predominance of hypertensive heart failure in the Abuja Heart Study cohort of urban Nigerians: a prospective clinical registry of 1515 de novo cases. Eur J Heart Fail 2003; 15: 835-842.
10. Izzo JL, Gradman AH. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin N Am 2004; 88: 1257-1271.
11. Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D et al. The causes, treatment and outcome of acute heart failure in 1006 Africans from 9 countries. Arc Intern Med 2012; 172(18): 1386-1394.
12. Talwar S, Siebenhofer A, Williams B, Nq l. Influence of hypertension, left ventricular hypertrophy and left ventricular systolic dysfunction on plasma N terminal pro BNP. Heart 2000; 83: 278-282.
13. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140.
14. Dieplinger B, Januzzi J, Steinmair M, Gabriel C, Poelz W, Haltmayer M et al. Analytical and clinical evaluation of a novel highisensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chem Acta 2009; 409: 33-40.
15. Dieplinger B, Egger M, Poelz W, Haltmayer M, Mueller T. Long-term stability of soluble ST2 in frozen plasma samples. Clin Biochem 2010; 43: 1169-1170.
16. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008; 54(4): 752-756.
17. Prickett TC, Yandle TG, Nicholls MG, ESpiner EA, Richards AM. Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochem Biophys Res Commun 2001; 286(3): 513-517.
18. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
19. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976; 37: 7-11.
20. Devereux RB, Alonso DB, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
21. Palmieri V, Dahlof B, DeQuattro V, Sharpe N, Bella JN, de Simone G et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999; 34: 1625-1632.
22. Jurcut R, Giusca S, La Gerche A, Vasile S, Ginghina C, Voigt JU. The echocardiographic assessment of the right ventricle: what to do in 2010? Eur J Echocardiogr 2010; 11: 81-96.
23. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117: 1538-1549.
24. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gamon J et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009; 2: 684-691.
25. Karaye KM, Sani MU. Factors associated with poor prognosis among patients admitted with heart failure in a Nigerian tertiary medical centre: a cross-sectional study. BMC Cardiovasc Disord 2008; 8: 16-18.
26. Daniels L, Clopton P, Iqbal N, Tran K, Maisel AS. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J 2010; 160(4): 721-728.
27. Shah K, Kop W, Christenson R, Diercks DB, Henderson S, Hanson K et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem 2011; 57: 874-882.
28. Fruhwald FM, Fahrleitner A, Watzinger N, Fruhwald S, Dobnig H, Shumacher M et al. Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. Eur Heart J 1999; 20: 1415-1423.
29. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett Jr JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976-982.
30. Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll MH. The effect of renal dysfunction on BNP, NT-proBNP and their ratio. Am J Clin Pathol 2010; 133: 14-23.
31. Milani RV, Drazner MH, Lavie CJ, Morin DP, Ventura HO. Progression from concentric left ventricular hypertrophy and normal ejection fraction to left ventricular dysfunction. Am J Cardiol 2011; 108: 992-996.